The Irish MedTech sector has secured another major global validation as Cork-based neonatal care startup NeuroBell officially closed a $5.5 million (€4.8 million) funding round. The investment, led by Irish venture capital firm Elkstone, will fund critical clinical rollouts, regulatory submissions, and commercial expansion in the United States for the company's pioneering artificial intelligence neonatal brain monitor, Luna.
Founded in 2023 by Dr. Mark O’Sullivan (CEO), Dr. Alison O’Shea (CSO), and Colm Murphy (CTO) as a spin-out from University College Cork (UCC) and the INFANT Research Centre, NeuroBell is addressing a critical and underserved area in modern pediatrics: undetected brain seizures in newborns.
The Seizure Silent Threat in Neonatal Care
Seizures affect approximately 2 to 3 per 1,000 live births in developed nations, rising significantly in low-resource environments. In newborn infants, the vast majority of seizures are "silent"-meaning they present with no physical symptoms, such as convulsions, twitching, or abnormal eye movements. If left untreated, prolonged seizures can lead to permanent developmental delays, cerebral palsy, or severe cognitive impairment.
Currently, detecting these seizures requires continuous electroencephalography (EEG) monitoring, which involves bulky machines, complex wiring, and constant oversight by specialized pediatric neurologists. In many neonatal intensive care units (NICUs), this equipment is in short supply, and interpretation of results can take hours, delaying life-saving interventions.
"Newborn brain injury can happen within minutes of a seizure starting," explained CEO Dr. Mark O’Sullivan. "Luna brings real-time, clinical-grade brain monitoring directly to the bedside, enabling doctors and nurses to intervene immediately without waiting for a specialist."
Luna: A Pocket-Sized AI EEG Solution
NeuroBell’s flagship technology, Luna, is a pocket-sized, completely wireless EEG device designed specifically for the unique environment of the NICU. By eliminating the mass of wires associated with traditional EEG setups, Luna reduces stress on the infant and simplifies application for nursing staff. Key advantages of the system include:
- AI-Powered Alerts: Luna uses machine learning algorithms developed over a decade of research at UCC to analyze brain waves in real time, automatically flagging suspected seizure activity.
- Bedside Decision Support: The system provides clear visual alerts for bedside clinicians, providing diagnostic support when pediatric neurologists are unavailable.
- Wireless Portability: Its compact design allows for easy integration during kangaroo care (skin-to-skin contact) and other neonatal therapies.
Global Backing and US Market Push
In addition to Elkstone, the funding round saw significant participation from the US-based health system Parkview Health, as well as returning backing from Furthr VC, Atlantic Bridge, the MedTech Syndicate, and Enterprise Ireland. This follows an earlier seed investment of €2.1 million in 2024, demonstrating strong, sustained investor confidence in NeuroBell's technological and clinical roadmap.
The inclusion of Parkview Health is particularly strategic. Based in Fort Wayne, Indiana, Parkview is partnering with NeuroBell to facilitate US clinical trials and pilot programmes. The capital injection will be primarily deployed to secure Food and Drug Administration (FDA) clearance in the United States, where the company has already established a corporate presence.
"NeuroBell represents the best of Irish deep-tech innovation," said Elkstone partner Suhasini Srinivasaragavan. "By combining UCC's academic excellence with commercial focus and global partnerships, they are poised to set a new standard of care in neonatal intensive care units worldwide."
AI Edge-Computing in Neonatal Intensive Care Units (NICUs)
NeuroBell's $5.5 million funding round, supported by leading MedTech venture capital syndicates and Enterprise Ireland, highlights the clinical potential of AI-driven medical devices in neonatal care. Neonatal seizures are a medical emergency, representing the most common sign of brain injury in newborns. If left untreated, they can lead to permanent neurological damage or cerebral palsy. However, detecting seizures in newborns is notoriously difficult, as they are often subclinical (showing no physical symptoms) and can only be identified via continuous electroencephalogram (EEG) monitoring.
NeuroBell has developed a portable, wireless EEG monitor called Luna that utilizes advanced edge-AI algorithms to analyze brain activity at the bedside. The device automatically detects seizure activity and alerts clinicians in real time, enabling immediate therapeutic intervention without the need for specialized neurophysiology staff to continuously interpret raw EEG waveforms.
Frequently Asked Questions
What is the primary function of NeuroBell's Luna monitor?
Luna is a portable neonatal seizure monitor that uses artificial intelligence to detect subclinical seizures in newborns in real time at the bedside, alerting ICU staff immediately.
Who led the $5.5 million funding round?
The funding round was led by specialized healthcare and technology venture capital funds, with follow-on support from regional investment syndicates and Enterprise Ireland.
How does edge-AI improve neonatal healthcare?
By processing EEG data directly on the device, Luna provides instant alerts to ICU nurses and doctors, bypassing the delays associated with transmitting raw data to external specialists for manual review.
Commercial Launch and Clinical Adoption Strategy
NeuroBell's successful funding round will accelerate the clinical validation and regulatory clearance of its Luna monitor in key global markets. The transition from academic research at UCC to commercial deployment highlights the strength of Ireland's MedTech incubation ecosystem. Securing partnerships with international neonatal intensive care units (NICUs) is the next vital step for market adoption.
